Article Text

Download PDFPDF

Welcome to EULAR’s guidelines for the use of big data techniques in rheumatic and musculoskeletal diseases. Response to: ‘On using machine learning algorithms to define clinically meaningful patient subgroups’ by Knevel and Huizinga
  1. Alain Meyer1,2,
  2. Lionel Spielmann3,
  3. François Séverac4,5
  1. 1Exploration Fonctionnelle Musculaire, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  2. 2Centre National de Référence des Maladies Auto-Immunes Systémiques Rares de l'Est et du Sud-Ouest, Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  3. 3Service de Rhumatologie, Hôpitaux civils de Colmar, Colmar, France
  4. 4Service de Santé Publique, GMRC, CHU de Strasbourg, Strasbourg, France
  5. 5ICube, UMR 7357, équipe IMAGeS, université de Strasbourg, Strasbourg, France
  1. Correspondence to Dr Lionel Spielmann, Service de Rhumatologie, Hospices civils de Colmar, Colmar 68000, France; lionel.spielmann{at}ch-colmar.fr

Statistics from Altmetric.com

We thank Knevel and Huizinga for their good comments1 on our work in which we used hierarchical clustering on principal components to define clinically meaningful subgroups of patients with anti-Ku antibodies2 and, to a lesser extent, on the work of Mariampillai et al3 in which the authors used a similar method to reveal subgroups of myositis and propose a classification of these diseases.

Knevel and Huizinga nicely explain how this statistical tool is a useful alternative to detailed insight in pathogenesis to improve taxonomy and personalise medicine. In this regards, myositis, which is rare and heterogeneous condition, is perfectly fitted for this method.

Knevel and Huizinga also challenge the concern about these techniques raised by Pinal-Fernandez and Mammen through a statistical sophistry.4 In this regards, the initiative started by the European League Against Rheumatism (EULAR) to guide the use of big data techniques for rheumatic and musculoskeletal diseases will help to promote the development and the standardisation of these tools.5

Finally, Knevel and Huizinga point out the importance of the validation of the findings. Given the extreme rarity of anti-Ku patients, we used k-fold cross-validation method as detailed by the authors.1 2 Furthermore, Mariampillai et al3 have used the independent cohort of 50 patients to confirm 4 groups of myositis they highlighted through hierarchical clustering on principal components analysis.

As a conclusion, myositis and related conditions are examples of musculoskeletal diseases that are well fitted for big data techniques such as hierarchical clustering on principal components. We welcome the initiative of EULAR to further improve the development and the standardisation of these techniques.5

References

View Abstract

Footnotes

  • Handling editor Josef S Smolen

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles